These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34155340)

  • 41. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses.
    Trachtenberg J; Weersink RA; Davidson SR; Haider MA; Bogaards A; Gertner MR; Evans A; Scherz A; Savard J; Chin JL; Wilson BC; Elhilali M
    BJU Int; 2008 Aug; 102(5):556-62. PubMed ID: 18494829
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Porphyrin-grafted Lipid Microbubbles for the Enhanced Efficacy of Photodynamic Therapy in Prostate Cancer through Ultrasound-controlled
    You Y; Liang X; Yin T; Chen M; Qiu C; Gao C; Wang X; Mao Y; Qu E; Dai Z; Zheng R
    Theranostics; 2018; 8(6):1665-1677. PubMed ID: 29556348
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer.
    Davidson SR; Weersink RA; Haider MA; Gertner MR; Bogaards A; Giewercer D; Scherz A; Sherar MD; Elhilali M; Chin JL; Trachtenberg J; Wilson BC
    Phys Med Biol; 2009 Apr; 54(8):2293-313. PubMed ID: 19305043
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response.
    Trachtenberg J; Bogaards A; Weersink RA; Haider MA; Evans A; McCluskey SA; Scherz A; Gertner MR; Yue C; Appu S; Aprikian A; Savard J; Wilson BC; Elhilali M
    J Urol; 2007 Nov; 178(5):1974-9; discussion 1979. PubMed ID: 17869307
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alternative- and focal therapy trends for prostate cancer: a total population analysis of in-patient treatments in Germany from 2006 to 2019.
    Flegar L; Zacharis A; Aksoy C; Heers H; Derigs M; Eisenmenger N; Borkowetz A; Groeben C; Huber J
    World J Urol; 2022 Jul; 40(7):1645-1652. PubMed ID: 35562598
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer.
    Kosharskyy B; Solban N; Chang SK; Rizvi I; Chang Y; Hasan T
    Cancer Res; 2006 Nov; 66(22):10953-8. PubMed ID: 17108133
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Endoscopic vascular targeted photodynamic therapy with the photosensitizer WST11 for benign prostatic hyperplasia in the preclinical dog model.
    Chevalier S; Cury FL; Scarlata E; El-Zayat E; Hamel L; Rocha J; Zouanat FZ; Moussa S; Scherz A; Elhilali M; Anidjar M
    J Urol; 2013 Nov; 190(5):1946-53. PubMed ID: 23680311
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary focal prostate radiotherapy: Do all patients really need whole-prostate irradiation?
    Jereczek-Fossa BA; Ciardo D; Petralia G; Bellomi M; De Bari B; De Cobelli O; Orecchia R
    Crit Rev Oncol Hematol; 2016 Sep; 105():100-11. PubMed ID: 27397485
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ultrasmall AGuIX theranostic nanoparticles for vascular-targeted interstitial photodynamic therapy of glioblastoma.
    Thomas E; Colombeau L; Gries M; Peterlini T; Mathieu C; Thomas N; Boura C; Frochot C; Vanderesse R; Lux F; Barberi-Heyob M; Tillement O
    Int J Nanomedicine; 2017; 12():7075-7088. PubMed ID: 29026302
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
    Yazici S; Kim SJ; Busby JE; He J; Thaker P; Yokoi K; Fan D; Fidler IJ
    Prostate; 2005 Nov; 65(3):203-15. PubMed ID: 15948138
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vascular-targeted photodynamic therapy (VTP) of a canine-transmissible venereal tumour in a murine model with Pd-bacteriopheophorbide (WST09).
    Vilensky J; Koudinova NV; Harmelin A; Scherz A; Salomon Y
    Vet Comp Oncol; 2005 Dec; 3(4):182-93. PubMed ID: 19754773
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting Phosphatidylinositol 3-Kinase Signaling Pathway for Therapeutic Enhancement of Vascular-Targeted Photodynamic Therapy.
    Kraus D; Palasuberniam P; Chen B
    Mol Cancer Ther; 2017 Nov; 16(11):2422-2431. PubMed ID: 28835385
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts.
    Dalrymple SL; Becker RE; Zhou H; DeWeese TL; Isaacs JT
    Prostate; 2012 May; 72(6):638-48. PubMed ID: 21837778
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Contrast enhanced ultrasound imaging can predict vascular-targeted photodynamic therapy induced tumor necrosis in small animals.
    Cornelis FH; Kim K; Durack JC; Jebiwott S; Scherz A; Srimathveeravalli G; Coleman JA
    Photodiagnosis Photodyn Ther; 2017 Dec; 20():165-168. PubMed ID: 28887222
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [
    Arbuznikova D; Klotsotyra A; Uhlmann L; Domogalla LC; Steinacker N; Mix M; Niedermann G; Spohn SKB; Freitag MT; Grosu AL; Meyer PT; Gratzke C; Eder M; Zamboglou C; Eder AC
    Theranostics; 2024; 14(6):2560-2572. PubMed ID: 38646643
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-time vascular imaging and photodynamic therapy efficacy with micelle-nanocarrier delivery of chlorin e6 to the microenvironment of melanoma.
    Lee CH; Lai PS; Lu YP; Chen HY; Chai CY; Tsai RK; Fang KT; Tsai MH; Hsu CY; Hung CC; Wu DC; Yu HS; Chang CH; Tsai DP
    J Dermatol Sci; 2015 Nov; 80(2):124-32. PubMed ID: 26360010
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors.
    Ngen EJ; Chen Y; Azad BB; Boinapally S; Jacob D; Lisok A; Shen C; Hossain MS; Jin J; Bhujwalla ZM; Pomper MG; Banerjee SR
    Nanotheranostics; 2021; 5(2):182-196. PubMed ID: 33564617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prostate cancer-derived CCN3 induces M2 macrophage infiltration and contributes to angiogenesis in prostate cancer microenvironment.
    Chen PC; Cheng HC; Wang J; Wang SW; Tai HC; Lin CW; Tang CH
    Oncotarget; 2014 Mar; 5(6):1595-608. PubMed ID: 24721786
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Decision Regret and Quality of Life after Focal Therapy with Vascular-Targeted Photodynamic Therapy (TOOKAD®) for Localized Prostate Cancer.
    Flegar L; Baunacke M; Buerk BT; Proschmann R; Zacharis A; Propping S; Huber J; Thomas C; Borkowetz A
    Urol Int; 2022; 106(9):903-908. PubMed ID: 34814157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.